The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

India's largest drugmaker Sun Pharmaceutical Industries Ltd and its peers Cipla Ltd., Glenmark ... and psychotropic drugs, as well as anti-retroviral drugs (including HIV-treating medicines).

In the following year, Cipla received approval from United States Food and Drug Administration (USFDA) to manufacture medicines in bulk for HIV. In 1994, Cipla introduced Deferiprone which was sta ...

The drug is the first injectable therapy for HIV PrEP, protecting against infection with just six doses a year. GSK also said the new agreements with Aurobindo, Cipla, and Viatris could lead to ...

Among the various therapeutic categories, anti-infective drugs continue to dominate the Indian market with c17% share (this excludes anti-HIV ... after Abbott and Cipla. Remaining MNCs include ...

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

The global HIV drugs industry was valued at USD 28.6 billion in 2023 and is projected to grow at a CAGR of 4.7% from 2024 to ...

In January, the White House ordered an immediate halt to the distribution of HIV medications by U.S.-funded foreign clinics, ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

North America was the major shareholder in 2022. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period. PO ...

Injections of semaglutide were associated with significant improvement in cognitive function in people living with HIV (PWH), ...